Table 1.
Effect of AAL-R on antigen-specific CD8+ T cells accumulation and viral titers
| Treatment | n | Day 5 after infection |
Day 7 after infection |
Day 8 after infection |
|||
|---|---|---|---|---|---|---|---|
| GP33-specific cells | Titer | GP33-specific cells | Titer | GP33-specific cells | Titer | ||
| VEH | 4 | 4.1 × 102 ± 1.1* | 14.3 × 104 ± 5.0‡ | 7.6 × 103 ± 2.0 | 3.9 × 102 ± 0.8 | 3.0 × 104 ± 1.3 | 1.3 × 102 (1/4)‡ |
| AAL-S | 4 | 3.3 × 102 ± 0.9 | 7.9 × 104 ± 2.0 | 4.7 × 103 ± 1.8 | 3.6 × 102 ± 0.9 | 3.8 × 104 ± 0.8 | 0.2 × 102 ± 0.03 (3/4) |
| AAL-R | 4 | 1.5 × 102 ± 0.5 | 6.9 × 104 ± 1.6 | 1.8 × 103 ± 0.2* | 26.0 × 102 ± 12.0 | 2.3 × 104 ± 0.8 | 10.1 × 102 ± 6.8 (2/4) |
Mice were infected with 1 × 105 PFU of FLU-LCMV and administered i.t. with VEH and or 0.1 mg/kg AAL-S or AAL-R 1 hpi. *, P ≤ 0.05 when compared to vehicle-treated mice.
*Values are presented as average number ± SEM.
†Values are presented as average PFU/g of tissue ± SEM.
‡Virus-positive mice/n.